| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 569,000 | 285,200 | 105,400 | 424,500 |
| Depreciation and amortization | 186,600 | 123,000 | 60,000 | 159,900 |
| Share-based compensation | 124,600 | 79,500 | 34,200 | 127,100 |
| Non-cash interest expense | 5,600 | 3,700 | 1,900 | 5,600 |
| Deferred income taxes | 103,300 | -14,700 | -5,800 | -68,100 |
| Net (gains) losses on equity investments | 78,100 | - | - | - |
| Other non-cash income and expenses | 18,700 | 12,700 | 12,300 | 63,300 |
| Accounts receivable, net | 95,700 | 333,500 | 148,900 | 27,600 |
| Inventory | 45,900 | 12,300 | -6,200 | 20,300 |
| Prepaid and other assets | 7,900 | 5,500 | -16,500 | 13,800 |
| Operating lease right-of-use assets and liabilities, net | 4,500 | 3,000 | 900 | 3,000 |
| Accounts payable and accrued liabilities | 357,100 | 359,400 | 125,400 | 231,700 |
| Accrued payroll and related expenses | 56,600 | 15,300 | -600 | -64,300 |
| Deferred revenue and other liabilities | -5,300 | 2,400 | 2,700 | -300 |
| Net cash provided by operating activities | 1,146,700 | 486,800 | 183,800 | 688,100 |
| Purchases of marketable securities | 1,246,600 | 1,070,700 | 462,500 | 2,083,500 |
| Proceeds from sale and maturity of marketable securities | 1,755,100 | 1,288,900 | 650,200 | 2,419,200 |
| Purchases of property and equipment | 261,600 | 181,100 | 87,000 | 234,200 |
| Purchases of non-marketable equity securities | 18,000 | - | - | - |
| Other investing activities | -500 | 500 | 500 | 5,300 |
| Net cash provided by investing activities | 229,400 | 36,600 | 100,200 | 96,200 |
| Net proceeds from issuance of common stock | 28,100 | 14,200 | 14,200 | 28,200 |
| Proceeds from issuance of senior convertible notes, net of issuance costs | - | - | - | 0 |
| Purchases of treasury stock | 187,200 | - | - | 750,000 |
| Payments for conversions of senior convertible notes | - | - | - | 0 |
| Purchases of capped call transactions | - | - | - | 0 |
| Other financing activities | -5,100 | -3,400 | -1,700 | -11,400 |
| Net cash used in financing activities | -164,200 | 10,800 | 12,500 | -733,200 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 17,700 | 18,800 | 2,300 | 3,800 |
| Increase in cash, cash equivalents and restricted cash | 1,229,600 | 553,000 | 298,800 | 54,900 |
| Cash and cash equivalents at beginning of period | 607,300 | - | - | - |
| Cash and cash equivalents at end of period | 1,836,900 | - | - | - |
DEXCOM INC (DXCM)
DEXCOM INC (DXCM)